While Australians can invest in some excellent local healthcare companies, there are limitations. For instance, they tend to be either single or narrow product device companies, says Monik Kotecha, Insync. Global pharmaceutical companies benefit from ageing demographics By 2005, 10 per cent of global population was aged over 60 By 2050, 22 per cent of […]
pharmaceutical companies
Insync Funds Management is a global equity specialist based in Sydney. Key team members own equity in the business and co-invest in the Fund alongside other investors.